Kelly Gold was appointed Director of X4 Pharmaceuticals, Inc, effective July 1, 2026. As of November 6, 2026, X4 Pharmaceuticals, Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 1, 2026, naming 1 appointment (Form 8-K, July 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like X4 Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
X4 Pharmaceuticals, Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-01. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as X4 Pharmaceuticals, Inc files it.
Also on the record for X4 Pharmaceuticals, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 4.6% of the class | 5%+ stakes | Source |
| September 21, 2026 | Stake report, Schedule 13G, by Venrock Healthcare Capital Partners III, L.P. | 5.6% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 8.33% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 8.1% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 7.3% of the class | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G/A, by Morgan Stanley | 10.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Saturn V Capital Management LP | 7.36% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BCLS II Equity Opportunities, LP | 7.43% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 3.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Trails Edge Capital Partners, LP | 5.8% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 2.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs X4 Pharmaceuticals, Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on X4 Pharmaceuticals, Inc and the records around it.
X4 Pharmaceuticals, Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Bain Capital Life Sciences Fund, L.P. also filed stake reports on 2 other companies: Rapid Micro Biosystems, Inc. (Aug 2026), Pharvaris N.V. (Feb 2026)
- Growth Equity Opportunities 18 VGE, LLC also filed stake reports on 2 other companies: Celcuity Inc. (Mar 2026), Gossamer Bio, Inc. (Feb 2026)
- Saturn V Capital Management LP also filed stake reports on 2 other companies: Monopar Therapeutics (Aug 2026), Immix Biopharma, Inc. (Feb 2026)
Watch X4 Pharmaceuticals, Inc
Get an email when X4 Pharmaceuticals, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on X4 Pharmaceuticals, Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on X4 Pharmaceuticals, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on X4 Pharmaceuticals, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 31 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-01 | In | Director | 2026-07-01 | 8-K, 2026-07-01 |
Who leads X4 Pharmaceuticals, Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Kelly Gold, appointed, effective 2026-07-01 (filed 2026-07-01).
New leaders reset buying decisions — get the Full Report on X4 Pharmaceuticals, Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at X4 Pharmaceuticals, Inc, with the record behind each one.
Find candidates like Director at X4 Pharmaceuticals, IncEvery change, in the filing's words
Appointed: Kelly Gold, Director, effective 2026-07-01
On June 30, 2026, of X4 Pharmaceuticals, Inc. (the "Company") appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026.
- In connection with Ms. Gold's appointment, the size of the Company's board of directors (the "Board") was increased from five to six directors.
- Ms. Gold has also been appointed to serve on the Audit Committee of the Board.
- Ms. Gold, age 49, has served as Chief Financial Officer of CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company (Nasdaq: CAMP), since April 2022.
- Ms. Gold previously served as CAMP4's Chief Business Officer from April 2021 to March 2022, and held positions of increasing responsibility in Finance and Corporate Development at CAMP4 from 2017 to March 2021.
- Ms. Gold previously served as Associate Director, Strategic Corporate Finance at Biogen Inc. (Nasdaq: BIIB) from 2014 to 2017, where she provided financial leadership for the company's late stage and marketed rare disease programs and developed long term strategic financial trajectories for the R&D organization.
- Ms. Gold also previously served as a Healthcare Investment Banking Associate at Deutsche Bank from 2009 to 2013, where she worked in the healthcare investment banking group.
- Ms. Gold earned bachelor's degrees in Life Sciences and Mechanical Engineering from Queen's University in Ontario and an MBA from the MIT Sloan School of Management.
Tools for this story
Each opens in a new tab, filled in for X4 Pharmaceuticals, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.